We found that 33.8% KRAS mutations co-occurred with other known targetable alterations (36.4% in KRAS G12C), which was similar to rates of co-mutation observed in NSCLC and CRC (Loong et al., 2020). This evidence concerns the gene KRAS and non-small cell lung carcinoma.